| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H10N4O3S2 |
| Molecular Weight | 286.331 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=NSN=C1NS(=O)(=O)C2=CC=C(N)C=C2
InChI
InChIKey=IZOYMGQQVNAMHS-UHFFFAOYSA-N
InChI=1S/C9H10N4O3S2/c1-16-9-8(11-17-12-9)13-18(14,15)7-4-2-6(10)3-5-7/h2-5H,10H2,1H3,(H,11,13)
| Molecular Formula | C9H10N4O3S2 |
| Molecular Weight | 286.331 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sulfametrole is a sulfonamide antibiotic used typically in combination with trimethoprim. Sulfametrole combined with trimethoprim could provide a choice for difficult-to-treat infections, particularly when administered intravenously. Sulfametrole/trimethoprim is an alternative sulphonamide/trimethoprim combination available in several EU countries, including Austria and the Netherlands. Sulphonamide/trimethoprim combination is the most active antibacterial but sulfametrole and sulfametrole/trimethoprim did not overcome resistance to sulfamethoxazole and sulfamethoxazole/trimethoprim in Enterobacteriaceae.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
